June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Hyaluronic acid based hydrogels for therapeutic delivery of adipose stem cells to corneal defects
Author Affiliations & Notes
  • Laura Koivusalo
    BioMediTech, University of Tampere, Kangasala, Finland
  • Jennika Karvinen
    Biomaterials and Tissue Engineering group, Tampere University of Technology, Tampere, Finland
  • Eetu Sorsa
    Biomaterials and Tissue Engineering group, Tampere University of Technology, Tampere, Finland
  • Susanna Miettinen
    BioMediTech, University of Tampere, Kangasala, Finland
  • Tanja Ilmarinen
    BioMediTech, University of Tampere, Kangasala, Finland
  • Minna Kellomäki
    Biomaterials and Tissue Engineering group, Tampere University of Technology, Tampere, Finland
  • Heli Skottman
    BioMediTech, University of Tampere, Kangasala, Finland
  • Footnotes
    Commercial Relationships   Laura Koivusalo, None; Jennika Karvinen, None; Eetu Sorsa, None; Susanna Miettinen, None; Tanja Ilmarinen, None; Minna Kellomäki, None; Heli Skottman, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 1410. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Laura Koivusalo, Jennika Karvinen, Eetu Sorsa, Susanna Miettinen, Tanja Ilmarinen, Minna Kellomäki, Heli Skottman; Hyaluronic acid based hydrogels for therapeutic delivery of adipose stem cells to corneal defects. Invest. Ophthalmol. Vis. Sci. 2017;58(8):1410.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Adipose stem cells (ASCs) have excellent therapeutic potential for treatment of corneal stromal defects, but feasible means of transplanting them is still lacking. In this study, we developed and compared two different hyaluronic acid (HA) hydrogels in order to evaluate their potential as a cell delivery vehicle to the corneal stroma. After preliminary tests, we then further modified the more promising HA-hydrogel by incorporating collagen I (CI) in the hydrogel structure. These HA based hydrogels are promising as corneal stromal biomaterials, as they form stable, crosslinked hydrogels rapidly in situ and are naturally degraded by enzymes in the body, without acidic degradation products.

Methods : We fabricated two hydrazone crosslinked HA hydrogels composed of differently synthesized HA components (HALD-HAADH and HAALD-HACDH). We then combined CI with the HAALD and HACDH components in order to increase the cellular inductivity of the hydrogel. The chemical structure of the crosslinked hydrogels was analyzed using Fourier transform infrared spectroscopy (FTIR). The hydrogels were also characterized for their swelling and degradation behavior and rheological, mechanical and optical properties. Human ASCs were incorporated into the hydrogels and cultured up to two weeks to determine cytocompatibility of the hydrogels, analyzed via PrestoBlue and Live/dead staining.

Results : Comparison between the two HA hydrogel combinations revealed that HAALD-HACDH had improved stability and higher stiffness over HALD-HAADH. HAALD-HACDH also had a higher refractive index (1.341) than HALD-HAADH (1.335). The addition of CI lowered the swelling ratio of the HAALD-HACDH hydrogel and increased its stiffness. In cytocompatibility studies, HALD-HAADH failed after three days due to hydrolytic degradation, but both HAALD-HACDH and HAALD-HACDH-CI maintained hASC viability and showed elongated cell morphology.

Conclusions : The HAALD-HACDH and HAALD-HACDH-CI hydrogels showed good cytocompatibility with hASCs, and had excellent optical properties. The cells can be injected to the damage site within gel precursor, the components gelate within a few seconds without any external linking agents or heat, and the hydrogels are naturally cleared by enzymatic degradation. Thus, we suggest these hydrogels as potential materials for ASC delivery to treat corneal stromal damages.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×